Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R.

Xenobiotica. 2019 Dec;49(12):1388-1395. doi: 10.1080/00498254.2019.1580403. Epub 2019 Mar 20.

PMID:
30739533
2.

Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.

Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE.

J Pharmacol Exp Ther. 2019 Feb;368(2):146-156. doi: 10.1124/jpet.118.251157. Epub 2018 Nov 12.

PMID:
30420360
3.

Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC.

Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL.

Front Pharmacol. 2018 Sep 26;9:1084. doi: 10.3389/fphar.2018.01084. eCollection 2018.

4.

Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.

Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A.

Biochem Biophys Res Commun. 2018 Apr 6;498(3):597-602. doi: 10.1016/j.bbrc.2018.03.028. Epub 2018 Mar 10.

5.

Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.

Ford BM, Franks LN, Radominska-Pandya A, Prather PL.

PLoS One. 2016 Dec 9;11(12):e0167240. doi: 10.1371/journal.pone.0167240. eCollection 2016.

6.

Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Dates CR, Fahmi T, Pyrek SJ, Yao-Borengasser A, Borowa-Mazgaj B, Bratton SM, Kadlubar SA, Mackenzie PI, Haun RS, Radominska-Pandya A.

Cancer Biol Ther. 2015;16(5):714-23. doi: 10.1080/15384047.2015.1026480.

7.

Nanodelivery of Parthenolide Using Functionalized Nanographene Enhances its Anticancer Activity.

Karmakar A, Xu Y, Mustafa T, Kannarpady G, Bratton SM, Radominska-Pandya A, Crooks PA, Biris AS.

RSC Adv. 2015 Jan 1;5(4):2411-2420.

8.

Single-walled carbon nanotube and graphene nanodelivery of gambogic acid increases its cytotoxicity in breast and pancreatic cancer cells.

Saeed LM, Mahmood M, Pyrek SJ, Fahmi T, Xu Y, Mustafa T, Nima ZA, Bratton SM, Casciano D, Dervishi E, Radominska-Pandya A, Biris AS.

J Appl Toxicol. 2014 Nov;34(11):1188-99. doi: 10.1002/jat.3018. Epub 2014 Sep 12.

9.

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, Finel M, Kadlubar SA, Radominska-Pandya A.

Drug Metab Dispos. 2014 Sep;42(9):1392-400. doi: 10.1124/dmd.114.058016. Epub 2014 Jun 10.

10.

Special issue: nanotechnology and disease.

Biris AS, Radominska-Pandya A.

Drug Metab Rev. 2014 May;46(2):127. doi: 10.3109/03602532.2014.903061. Epub 2014 Mar 28. No abstract available.

PMID:
24678874
11.

Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases.

Greer AK, Madadi NR, Bratton SM, Eddy SD, Mazerska Z, Hendrickson HP, Crooks PA, Radominska-Pandya A.

Chem Res Toxicol. 2014 Apr 21;27(4):536-45. doi: 10.1021/tx400408x. Epub 2014 Mar 11.

12.

Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.

Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH.

Drug Metab Lett. 2013 Mar;7(1):34-8.

13.

Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds.

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH.

Forensic Sci Int. 2013 Dec 10;233(1-3):416-22. doi: 10.1016/j.forsciint.2013.10.002. Epub 2013 Oct 14.

PMID:
24314548
14.

CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.

Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A.

Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: 10.1016/j.bbrc.2013.10.057. Epub 2013 Oct 19.

15.

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL.

Life Sci. 2014 Feb 27;97(1):45-54. doi: 10.1016/j.lfs.2013.09.017. Epub 2013 Sep 29. Review.

16.

Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology.

Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH.

Anal Chem. 2013 Oct 1;85(19):9390-9. doi: 10.1021/ac4024704. Epub 2013 Sep 12.

PMID:
23987522
17.

K2 toxicity: fatal case of psychiatric complications following AM2201 exposure.

Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH.

J Forensic Sci. 2013 Nov;58(6):1676-80. doi: 10.1111/1556-4029.12216. Epub 2013 Jul 3.

18.

Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Pawlowska M, Chu R, Fedejko-Kap B, Augustin E, Mazerska Z, Radominska-Pandya A, Chambers TC.

Drug Metab Dispos. 2013 Feb;41(2):414-21. doi: 10.1124/dmd.112.047811. Epub 2012 Nov 16.

19.

Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH.

Drug Metab Dispos. 2012 Nov;40(11):2174-84. doi: 10.1124/dmd.112.047530. Epub 2012 Aug 17.

20.

Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Fedejko-Kap B, Bratton SM, Finel M, Radominska-Pandya A, Mazerska Z.

Drug Metab Dispos. 2012 Sep;40(9):1736-43. doi: 10.1124/dmd.112.045401. Epub 2012 Jun 1.

21.

A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL.

Chem Res Toxicol. 2012 Apr 16;25(4):825-7. doi: 10.1021/tx3000472. Epub 2012 Mar 15.

22.

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL.

Biochem Pharmacol. 2012 Apr 1;83(7):952-61. doi: 10.1016/j.bcp.2012.01.004. Epub 2012 Jan 18.

23.

Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.

Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A.

J Pharmacol Exp Ther. 2012 Jan;340(1):46-55. doi: 10.1124/jpet.111.184721. Epub 2011 Oct 4.

24.

Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors.

Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A.

Xenobiotica. 2012 Feb;42(2):139-56. doi: 10.3109/00498254.2011.609570. Epub 2011 Oct 4.

25.

Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells.

Fedejko-Kap B, Niemira M, Radominska-Pandya A, Mazerska Z.

Xenobiotica. 2011 Dec;41(12):1044-55. doi: 10.3109/00498254.2011.604743. Epub 2011 Aug 23.

PMID:
21859392
26.

Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Höglund C, Sneitz N, Radominska-Pandya A, Laakonen L, Finel M.

Steroids. 2011 Dec 11;76(13):1465-73. doi: 10.1016/j.steroids.2011.07.017. Epub 2011 Aug 9.

27.

Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases.

Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, Radominska-Pandya A.

Drug Metab Dispos. 2011 Oct;39(10):1967-76. doi: 10.1124/dmd.111.040709. Epub 2011 Jul 11.

28.

Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine.

Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Aug 15;83(16):6381-8. doi: 10.1021/ac201377m. Epub 2011 Jul 27.

29.

Ethylenediamine functionalized-single-walled nanotube (f-SWNT)-assisted in vitro delivery of the oncogene suppressor p53 gene to breast cancer MCF-7 cells.

Karmakar A, Bratton SM, Dervishi E, Ghosh A, Mahmood M, Xu Y, Saeed LM, Mustafa T, Casciano D, Radominska-Pandya A, Biris AS.

Int J Nanomedicine. 2011;6:1045-55. doi: 10.2147/IJN.S17684. Epub 2011 May 18.

30.

Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Jun 1;83(11):4228-36. doi: 10.1021/ac2005636. Epub 2011 May 6.

31.

Preface.

Radominska-Pandya A.

Drug Metab Rev. 2010 Feb;42(1):1-2. doi: 10.3109/03602530903205450. No abstract available.

PMID:
20070243
32.
33.

Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.

Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH.

Chem Res Toxicol. 2009 Jul;22(7):1239-45. doi: 10.1021/tx900031z.

34.

Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.

Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH.

Drug Metab Dispos. 2009 Jul;37(7):1496-504. doi: 10.1124/dmd.109.026898. Epub 2009 Apr 1.

35.

Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10.

Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, Finel M.

Drug Metab Dispos. 2009 Apr;37(4):768-75. doi: 10.1124/dmd.108.025692. Epub 2008 Dec 30.

36.

Effect of retinoids on UDP-glucuronosyltransferase 2B7 mRNA expression in Caco-2 cells.

Lu Y, Bratton S, Heydel JM, Radominska-Pandya A.

Drug Metab Pharmacokinet. 2008;23(5):364-72.

37.

Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin.

Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A.

Drug Metab Dispos. 2008 Nov;36(11):2211-8. doi: 10.1124/dmd.108.022863. Epub 2008 Aug 25.

38.

Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues.

Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A.

Steroids. 2008 Jul;73(6):611-20. doi: 10.1016/j.steroids.2008.01.019. Epub 2008 Feb 3. Erratum in: Steroids. 2009 Jun;74(6):548-9.

39.

The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis.

Xiong Y, Patana AS, Miley MJ, Zielinska AK, Bratton SM, Miller GP, Goldman A, Finel M, Redinbo MR, Radominska-Pandya A.

Drug Metab Dispos. 2008 Mar;36(3):517-22. Epub 2007 Nov 29.

40.

Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene.

Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A.

Steroids. 2008 Jan;73(1):139-47. Epub 2007 Sep 29.

41.

Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases.

Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH.

J Pharmacol Exp Ther. 2008 Jan;324(1):139-48. Epub 2007 Oct 5.

42.

Human UGT1A8 and UGT1A10 mRNA are expressed in primary human hepatocytes.

Li X, Bratton S, Radominska-Pandya A.

Drug Metab Pharmacokinet. 2007 Jun;22(3):152-61.

43.

Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.

Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR.

J Mol Biol. 2007 Jun 1;369(2):498-511. Epub 2007 Mar 30.

44.

CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling.

Collom SL, Jamakhandi AP, Tackett AJ, Radominska-Pandya A, Miller GP.

Arch Biochem Biophys. 2007 Mar 1;459(1):59-69. Epub 2006 Nov 2.

45.

Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10.

Starlard-Davenport A, Xiong Y, Bratton S, Gallus-Zawada A, Finel M, Radominska-Pandya A.

Steroids. 2007 Jan;72(1):85-94. Epub 2006 Dec 15.

46.

Sulfation of the isoflavones genistein and daidzein in human and rat liver and gastrointestinal tract.

Ronis MJ, Little JM, Barone GW, Chen G, Radominska-Pandya A, Badger TM.

J Med Food. 2006 Fall;9(3):348-55.

PMID:
17004897
47.

Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells.

Sabolovic N, Humbert AC, Radominska-Pandya A, Magdalou J.

Biopharm Drug Dispos. 2006 May;27(4):181-9.

PMID:
16477579
48.

Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis.

Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, Radominska-Pandya A.

Biochemistry. 2006 Feb 21;45(7):2322-32.

PMID:
16475821
49.

Structure of UDP-glucuronosyltransferases in membranes.

Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, Magdalou J.

Methods Enzymol. 2005;400:116-47. Review.

PMID:
16399347
50.

Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity.

Finel M, Li X, Gardner-Stephen D, Bratton S, Mackenzie PI, Radominska-Pandya A.

J Pharmacol Exp Ther. 2005 Dec;315(3):1143-9. Epub 2005 Aug 24.

PMID:
16120810

Supplemental Content

Loading ...
Support Center